| scholarly article | Q13442814 |
| P2093 | author name string | Wei Tang | |
| Qian Li | |||
| Yu-Ting Liu | |||
| Di Fan | |||
| Jian-Ping Zuo | |||
| Ze-Min Lin | |||
| Xiao-Qian Yang | |||
| Shi-Qi Cao | |||
| Feng-Hua Zhu | |||
| Shi-Jun He | |||
| Mei-Juan Shao | |||
| Fang-Ming Yang | |||
| P2860 | cites work | The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) | Q80347907 |
| TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease | Q81040935 | ||
| Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences | Q81880357 | ||
| Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study | Q88067409 | ||
| Artemisinin analogue SM934 ameliorates DSS-induced mouse ulcerative colitis via suppressing neutrophils and macrophages | Q88924937 | ||
| Kinetics of Corneal Antigen Presenting Cells in Experimental Dry Eye Disease | Q89928664 | ||
| Ocular mucins in dry eye disease | Q92040385 | ||
| Corrigendum to "TFOS DEWS II pathophysiology report" [Ocul. Surf. 15 (3) (2017) 438-510] | Q92545653 | ||
| The ocular surface epithelial barrier and other mechanisms of mucosal protection: from allergy to infectious diseases | Q26865809 | ||
| The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells | Q30353026 | ||
| New tools for the evaluation of toxic ocular surface changes in the rat. | Q33308447 | ||
| Changes in corneal epithelial layer inflammatory cells in aqueous tear-deficient dry eye. | Q33486416 | ||
| SM934 treated lupus-prone NZB × NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development | Q34184574 | ||
| Dry Eye Disease: Impact on Quality of Life and Vision | Q34346990 | ||
| Topical omega-3 and omega-6 fatty acids for treatment of dry eye. | Q34749224 | ||
| Artemisinin analogue SM934 ameliorates murine experimental autoimmune encephalomyelitis through enhancing the expansion and functions of regulatory T cell | Q34979858 | ||
| Artemisinin analogue SM934 ameliorates the proteinuria and renal fibrosis in rat experimental membranous nephropathy | Q35080166 | ||
| Innate immune recognition of cancer | Q35549322 | ||
| α-Melanocyte-stimulating hormone ameliorates ocular surface dysfunctions and lesions in a scopolamine-induced dry eye model via PKA-CREB and MEK-Erk pathways | Q36388893 | ||
| Effect of desiccating environmental stress versus systemic muscarinic AChR blockade on dry eye immunopathogenesis | Q36758312 | ||
| Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation | Q36870048 | ||
| Inflammatory Response to Lipopolysaccharide on the Ocular Surface in a Murine Dry Eye Model. | Q36872927 | ||
| Dry eye disease: an immune-mediated ocular surface disorder | Q36916372 | ||
| Expression of toll-like receptor 4 contributes to corneal inflammation in experimental dry eye disease | Q37013881 | ||
| Benzalkonium chloride and glaucoma | Q37710684 | ||
| A Comparison of the Effects of Benzalkonium Chloride on Ocular Surfaces between C57BL/6 and BALB/c Mice. | Q37729041 | ||
| Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists | Q37888136 | ||
| TFOS DEWS II Tear Film Report. | Q38652990 | ||
| TFOS DEWS II Epidemiology Report | Q38652994 | ||
| TFOS DEWS II Definition and Classification Report. | Q38665717 | ||
| Ocular inflammation and corneal permeability alteration by benzalkonium chloride in rats: a protective effect of a myosin light chain kinase inhibitor | Q39990324 | ||
| Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface | Q45158772 | ||
| Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters | Q46586123 | ||
| Protective effects of carbenoxolone, an 11β-HSD1 inhibitor, against chemical induced dry eye syndrome. | Q50193141 | ||
| Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. | Q50721017 | ||
| Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. | Q51477256 | ||
| Downregulation of the NLRP3 inflammasome by adiponectin rescues Duchenne muscular dystrophy. | Q51737740 | ||
| Chemokine receptor CCR5 expression in conjunctival epithelium of patients with dry eye syndrome. | Q54602794 | ||
| High-Mobility Group Box 1 in Dry Eye Inflammation. | Q55010929 | ||
| MyD88 Deficiency Protects Against Dry Eye–Induced Damage. | Q55355486 | ||
| Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury | Q79839081 | ||
| Synthesis and immunosuppressive activity of new artemisinin derivatives. Part 2: 2-[12(beta or alpha)-dihydroartemisinoxymethyl(or 1'-ethyl)]phenoxyl propionic acids and esters | Q80110208 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P921 | main subject | NF-κB | Q411114 |
| eye disease | Q3041498 | ||
| P577 | publication date | 2020-08-03 | |
| P1433 | published in | Acta Pharmacologica Sinica | Q15749885 |
| P1476 | title | The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-κB/NLRP3 signaling |
Search more.